Clevudine for hepatitis B

Drugs of Today

Volumn 45, Issue 5, 2009, Pages 331-350

  Anderson, David Leif ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; CARBON 11; CIRCULAR DNA; CLEVUDINE; EMTRICITABINE; ENTECAVIR; FIALURIDINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RADIOPHARMACEUTICAL AGENT; REVOVIR; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; CREATINE KINASE BLOOD LEVEL; DRUG ACTIVATION; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOTOPE LABELING; LACTIC ACIDOSIS; LIVER FAILURE; LOW DRUG DOSE; MIXED INFECTION; MUSCLE NECROSIS; MUSCLE WEAKNESS; MYOPATHY; NEUROTOXICITY; NONHUMAN; OPTIMAL DRUG DOSE; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS MUTATION;

ANIMALS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; HEPATITIS B, CHRONIC; HUMANS;

EID: 69249176196     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.5.1377596     Document Type: Review

References (147)

1. Dienstag, J.L. Hepatitis B virus infection. N Engl J Med 2008, 359(14): 1486-1500
2. National Institutes of Health (US). Clinicaltrials.gov. Available at http://www.clinicaltrials.gov. Accessed 9 December 2008
3. Pharmasset, Inc., Princeton, NJ, Data on file. Available at http://www.pharmasset.com. Accessed 9 December 2008.
4. Bukwang Pharmaceutical Co, Limited, Seoul, South Korea. Bukwang Pharma: Contributing to society by pursuing a healthy paradise. Available at http://www.bukwang.co.kr/e/index.asp. Accessed 9 December 2008.
5. Clinical Care Options. HBV Providers' Choice in Prime Time: Efficacy, resistance and durability [official coverage of AASLD 2008]. Available at http://www.clinicaloptions.com/Hepatitis/Treatment%20Updates/HBV%20Prime%20Time/ Interactive%20Virtual%20Presentations/Locarnini%20Slides.aspx. Accessed 9 December 2008.
6. Clinical Care Options. CCO Official Conference Coverage: HBV expert recap of AASLD 2008. Available at http://www.clinicaloptions.com/Hepatitis/ Conference%20Coverage/AASLD%202008/Virtual%20Presentation%20Programs/HBV.aspx. Accessed 9 December 2008.
7. Cohen, S.M. 59th American Association for the Study of Liver Diseases Meeting [CME accredited slide kit based on AASLD]]. Available at http://www.hivandhepatitis.com/cme/2008/AASLD/docs/AASLD-FINAL.ppt. Accessed 9 December 2008.
8. Yoo, B.C., Kim, J. H., Chung, Y.-H. et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBe-Ag-positive chronic hepatitis B [Study 301]. Hepatology 2007, 45(5): 1172-1178
9. Yoo, B.C., Kim, J. H., Kim, T.H. et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression [Study 302]. Hepatology 2007, 46(4): 1041-1048
10. Cheong, J.Y. Management of chronic hepatitis B in treat-ment-naïve patients [article in Korean] Korean J Gastroenterol 2008, 51(6): 338-345
11. Yim, H.J. Management of antiviral-resistant chronic hepatitis B virus infection [article in Korean]. Korean J Gastroenterol 2008, 51(6): 346-359
12. Chu, C.K., Hong, J.H., Choi, Y. et al. L-FMAU: Clevudine. Drugs Fut 1998, 23(8): 821-826
13. Hui, C. K., Lau, G.K. Clevudine for the treatment of chronic hepatitis B virus infection. Expert Opin Investig Drugs 2005, 14(10): 1277-1284 (Pubitemid 41488876)
14. Korba, B.E., Furman, P.A., Otto, M.J. Clevudine: A potent inhibitor of hepatitis B virus in vitro and in vivo. Expert Rev Anti Infect Ther 2006, 4(4): 549-561 (Pubitemid 44523935)
15. Asselah, T., Moucari, R., Marcellin, P. Clevudine: A promising therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2008, 17(12): 1963-1974
16. Kwon, S., Ko, S., Choe, W. et al. Efficacy and safety of clevudine in chronic hepatitis B patients: A 48-week prospective study. Abstract 943. Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, California, October 31-November 4, 2008. Available at http://aasld.scientificabstracts.org. Accessed 9 December 2008.
17. Kim, K, Kim, M., Lee, J. et al. Efficacy of 48 week-clevudine treatment in patiients with chronic hepatitis B. Abstract 966. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, California, October 31-November 4, 2008 Available at http://aasld.scientificabstracts.org. 9 December 2008.
18. Lau, G.K., Hui, C.K., Leung, N. et al. Clevudine was superior to lamivudine in patients witt HbeAg+ chronic hepatitis B. Abstract 911. Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, California, October 31-November 4, 2008. Available at http://aasld.scientificabstracts.org. Accessed 9 December 2008.
19. Lau, G.K., Leung, N., Hui, C.K. et al. Clevudine was superior to lamivudine in the patients with HBeAg(+) chronic hepatitis B [Study 310]. Presented at the 18th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Seoul, South Korea, March 23-26, 2008. Available at http://www.pharmasset.com/pipeline/clevudine-publications.asp, accessed 18 June 2008.
20. Yuen, M.-F., Lai, C.-L. Current and future antiviral agents for chronic hepatitis B. J Antimicrob Chemother 2003, 51: 481-485. Available at http://jac.oxfordjournals.org/cgi/reprint/51/3/481.pdf?ck=nck, accessed 9 December 2008.
21. GlaxoSmithKline, Research Triangle Park, NC Epivir-HBV® (lamivudine) prescribing information, October 2007. Available at http://us.gsk.com/products/ assets/us-epivir-hbv.pdf, accessed 9 December 2008.
22. Gilead Sciences, Inc. Hepsera® (adefovir dipivoxil) prescribing information, May 2008. Available at http://www.hepsera.com/pdf/GIL214-07- Hepsera-PDF.8.pdf, accessed 9 December 2008.
23. Bristol-Myers Squibb, Princeton, NJ. Baraclude® (entecavir) prescribing information, July 2008. Available at http://packageinserts.bms.com/ pi/pi-baraclude.pdf, accessed 9 December 2008.
24. Novartis Pharmaceuticals Corporation, East Hanover, NJ. Tyzeka® (telblvudine) prescribing information. Available at http://www.pharma.us. novartis.com/product/pi/pdf/tyzeka.pdf, accessed 9 December 2008.
25. Gilead Sciences, Inc., Foster City, CA. Viread® (tenofovir disoproxil fumarate) prescribing information, November 2008. Available at http://www.viread.com/pdf/Viread-FPI.pdf, accessed 9 December 2008.
26. Gilead Sciences, Inc., Foster City, CA. Emtriva® (emtricitabine) prescribing information, May 2008. Available at http://www.gileadhiv.com/pdf/ EmtrivaFPI.pdf, accessed 9 December 2008.
27. Lok, A.S., McMahon, B.J. AASLD practice guidelines: Chronic hepatitis B. Hepatology 2007, 45(2): 507-39. Correction in Hepatology 2007, 45(6): 1347.
28. Marcellin, P., Heathcote, E.J., Buti, M. et al. Tenofovir disoproxil fumarate vs. adefovir for chronic hepatitis B. N Engl J Med 2008, 59(23): 2442-2455
29. Loomba, R., Rowley, A., Wesley, R. et al. Systematic review: The effect of preventative lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008, 148(7): 519-528 (Pubitemid 351665421)
30. Rivkin, A. Entecavir: A new nucleoside analogue for the treatment of chronic hepatitis B. Drugs Today 2007, 43(4): 201-20.
31. Tsunoda, S.M., Hassanein, T. Telbivudine for the treatment of hepatitis B disease. Future Virology 2008, 3(6): 517-527
32. Dusheiko, G., Danta, M. Telbivudine for the treatment of chronic hepatitis B. Drugs Today 2007, 43(5): 293-304.
33. Hammer, S.M., Eron, J.J., Jr., Reiss, P. et al. Antiretroviral treatment of adult HIV infections: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008, 300(5): 555-570
34. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1-139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf, accessed 9 December 2008.
35. Gilead Sciences, Inc., Foster City, CA. Truvada® (emtricitabine/ tenofovir disoproxil fumarate) prescribing information, November 2008. Available at http://www.gilead.com/pdf/truvada-pi.pdf, accessed 9 December 2008.
36. Centers for Disease Control and Prevention (US). Hepatitis, viral, type B. Available at http://www.cdc.gov/travel/yellowBookCh4-HepB.aspx , 92 December 2008.
37. Lavanchy, D. Hepatitis B epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11(2): 97-107. (Pubitemid 38365759)
38. Lavanchy, D. Worldwide epidemiology of HBV Infection, disease burden, and vaccine prevention. J Clin Virol 2005, 34 (Suppl. 1): S1-S3. (Pubitemid 43197742)
39. Lesmana, L.A., Leung, N.W.-Y., Mahachai, V. et al. Hepatitis B: overview of the burden of disease in the Asia-Pacific region. Liver Intl 2006, 26(S2): 3-10. (Pubitemid 44697930)
40. Saikia, N., Talukdar, R., Mazumder, S. et al. Management of patients with HBeAg-negative chronic hepatitis B. Postgrad Med J 2007, 83(975): 32-39 (Pubitemid 46253585)
41. Centers for Disease Control and Prevention (US). Hepatitis B: Frequently asked questions. Available at http://www.cdc.gov/ncidod/diseases/hepatitis/b/ faqb.htm, accessed 9 December 2008.
42. But, D.Y., Lai, C.L., Yuen, M.F. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008, 14(11): 1652-1656
43. Chen, C.J., Iloeje, U.H., Yang, H.I. Long-term outcomes in hepatitis B: The REVEAL-HBV study. Clin Liver Dis 2007, 11(4): 797-816.
44. Chen, C.-J., Yang, H.-I., Su, J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295(1): 65-73. (Pubitemid 43042691)
45. Iloeje, U.H., Yang, H.I., Jen, C.L. et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gasteroenterol Hepatol 2007, 5(8): 921-931. (Pubitemid 47161142)
46. Iloeje, U.H., Yang, H.I, Su, J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130(3): 678-686 (Pubitemid 43374518)
47. Wilt, T.J., Shamliyan, T., Shaukat, A. et al. Management of Chronic Hepatitis B. AHRQ Publication No. 09-E002, October 2008. Available at http://www.ahrq.gov/downloads/pub/evidence/pdf/hepb/hepb.pdf, accessed 9 December 2008.
48. Sorrell, M.F., Belongia, E.A., Costa, J. et al. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis B (draft statement 22 October 2008). Available at http://consensus.nih.gov/2008/ 2008HepatitisBCDC120main.htm, accessed 9 December 2008.
49. Keeffe, E.B., Zeuzem, S., Koff, R.S. et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007, 5(8): 890-897 (Pubitemid 47127032)
50. Lok, A.S. Navigating the maze of hepatitis B treatments. Gastroenterology 2007, 132(4): 1586-94. Erratum in Gastroenterology 2007, 133(12): 2077.
51. Feld, J.J., Ghany, M.G. Evolution of therapy for chronic hepatitis B: Progressing from the simple to the complex (editorial). Ann Intern Med 2007, 147(1): 806-808
52. Wieland, S.F., Chisari, F.V. Stealth and cunning: Hepatitis B and hepatitis C viruses. J Virol 2005, 79(15): 9369-9380
53. Alazawi, W., Foster, G.R. Advances in the diagnosis and treatment of hepatitis B. Curr Opin Infect Dis 2008, 21(5): 508-515
54. Ayoub, W.S., Keeffe, E.B. Review article: Current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2008, 28(2): 167-177 (Pubitemid 351861968)
55. Degertekin, B., Lok, A.S.F. Update on viral hepatitis: 2007. Curr Opin Gastroenterol 2008; 24(3): 306-311
56. Dusheiko, G., Antonakopoulos, N. Current treatment of hepatitis B. Gut 2008, 57: 105-24. Erratum Gut 2008, 57(6): 872.
57. Lau, D.T.-Y., Bleibel, W. Current status of antiviral therapy for hepatitis B. Therapeutic Advances in Gastroenterology. 2008, 1(1): 61-75. Available at http://tag.sagepub.com/cgi/reprint/1/1/61. Accessed 9 December 2008.
58. Leung, N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int 2008, 2(2): 163-78. Available at http://www.springerlink.com/content/b055058016152188/fulltext.pdf, accessed 9 December 2008. (Pubitemid 351650144)
59. Liaw, Y.-F., Leung, N. Kao, J.-H. et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2008, DOI: 10.1007/s12072-008-9080-3. Available at http://www.springerlink.com/ content/du475u12q655175j/fulltext.pdf, accessed 9 December 2008.
60. Lok, A.S.F. Therapy of chronic hepatitis B: Who to treat and when to treat? A case-based discussion. In Hepatitis Annual Update 2008; eds. Craig, M.A., King, E, Schultz, J. Available at http://clinicaloptions.com/Hepatitis/ Annual%20Updates/2008%20Annual%20Update.aspx. Accessed 9 December, 2008.
61. Singh, N.A., Reau, N. Management of hepatitis B virus. J Antimicrob Chemother 2008, DOI: 10.1093/jac/dkn188. Available at http://jac.oxfordjournals. org/cgi/reprint/dkn188v1. Accessed 9 December 2008.
62. Sheldon, J., Soriano, V. Hepatitis B escape mutations induced by antiviral therapy. J Antimicrob Chemother 2008, 61: 766-768
63. Keeffe, E.B., Dieterich, D.T., Pawlotsky, J.-M., Benhamou, Y. Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol 2008, 6(3): 268-74. (Pubitemid 351324881)
64. Lok, A.S., Zoulim, F., Locarnini, S., et al. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 2007, 46(1): 254-265 (Pubitemid 47171942)
65. Liu, W.C., Phiet, P.H., Chiang, T.Y. et al. Five subgenotypes of hepatitis B virus genotype B with distinct geographic and virological characteristics. Virus Res 2007, 129(2): 212-223 (Pubitemid 47588438)
66. Liu, C.-J., Kao, J.H. Genetic variability of hepatitis B virus and response to antiviral therapy. Antiviral Ther 2008, 13(5): 613-24.
67. Krarup, H., Madsen, P., Bentzen-Petersen, A. et al. Higher levels of HBV-DNA in genotypes B and C compared with genotypes A and D. Abstract 870. Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, California, October 31-November 4, 2008. Available at http://aasld.scientificabstracts.org. Accessed 9 December 2008.
68. Dao, D.Y., Yuan, R., Joshi, N. et al. Non-A hepatitis B genotypes are associated with more liver fibrosis in HIV/HBV. Abstract 869. Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, California, October 31-November 4, 2008. Available at http://aasld.scientificabstracts.org. Accessed 9 December 2008.
69. Papatheodoridis, G.V., Deutsch, M. Resistance issues in treating chronic hepatitis B. Fut Microbiol 2008, 13(5): 525-38.
70. Karatayli, E., Karayalçin, S., Karaasian, H. et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antiviral Ther 2007, 12(5): 761-768 (Pubitemid 47235490)
71. Weber, R., Dabin, C.A., Friis-Møller, N. et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 2006, 166(15): 1632-1641 (Pubitemid 44232373)
72. Bottecchia, M., Garcia-Samaniego, J., Soriano, V. The implications of antiviral drugs with activity against hepatitis B virus and HIV. Curr Opin Infect Dis 2007, 20(6): 621-628 (Pubitemid 350059522)
73. Dieterich, D.T. Special considerations and treatment of patients with HBV-HIV coinfection. Antiviral Ther 2007, 12(Suppl. 3): H43-H51.
74. Cheruvu, S., Marks, K., Talal, A.H. Understanding the pathogenesis and management of hepatitis B/HIV and hepatitis B/hepatitis C virus coinfection. Clin Liver Dis 2007, 11(4): 917-943 (Pubitemid 350019027)
75. Iser, D.M., Sasadeusz, J.J. Current treatment of HIV/hepatitis B virus coinfection. J Gastroenterol Hepatol 2008, 23(5): 699-706.
76. Kitchell, E., Jain, M.K. Evaluation and treatment of the patient coinfected with hepatitis B and HIV. Curr HIV/AIDS Rep 2008, 5(3): 103-111
77. Rockstroh, J.K., Bhagani, S., Benhamou, Y. et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008, 9(2): 82-88 (Pubitemid 351228130)
78. Sulkowski, M.S. Viral hepatitis and HIV coinfection. J Hepatol 2008, 48(2): 353-367
79. McMahon, M.A., Jilek, B.L., Brennan, T.P. et al. The HBV drug entecavir effects on HIV-1 replication and resistance. N Engl J Med 2007, 356: 2614-2621
80. Sasadeusz, J, Audsley, J, Mijch, A. et al. The anti-HIV activity of entecavir: A multicentre evaluation of lamivudine-experienced and lamivudine-naïve patients. AIDS 2008, 22(8): 947-955 (Pubitemid 351652245)
81. Zennou, V., Keilman, M., Otto, M.J., Furman, P. Anti-HIV activity and resistance profiles of entecavir compared to clevudine. Presented at the XVI International HIV Drug Resistance Workshop, Barbados, June 12-16, 2007. Available at http://www.pharmasset.com/pipeline/clevudine-publications.asp. Accessed 9 December 2008.
82. Chien, R.-N. Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with hepatitis B. Hepatol Int DOI: 10.1007/s12072-088-9066-1. Available at http://www.springerlink.com/content/ b66l438060nutn02/, 9 December 2008.
83. Casey, J., Cote, P.J., Toshkov, I.A. et al. Clevudine inhibits hepatitis delta virus viremia: A pilot study in chronically infected woodchucks. Antimicrob Agents Chemother 2005, 49(10): 4396-4399 (Pubitemid 41400998)
84. Inada, M., Yokosuka, O. Current antiviral therapies for chronic hepatitis B. Hepatol Res 2008, 38(6): 535-542 (Pubitemid 351622278)
85. Keeffe, E.B., Marcellin, P. New and emerging treatment of chronic hepatitis B. Clin Gastroenterol Hepatol 2007, 5(3): 285-294
86. Mathé, C., Gosselin, G. L-nucleoside enantiomers as antiviral drugs: A mini-review. Antiviral Res 2006, 71(2-3): 276-81. (Pubitemid 44226489)
87. Ma, T., Zhu, Y.L., Shanmuganathan, K. et al. Structure-activity relationships of 1-(2-deoxy-2-fluoro-1-β-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents. J Med Chem 1996, 39(14):2835-2843 (Pubitemid 26240351)
88. Kocic, I. Clevudine. University of Georgia/Abbott/Bukwang/Triangle/Yale University. Curr Opin Investig Drugs 2000, 1(3): 308-313
89. Abbruzzese, J.L., Schmidt, S., Raber, M.N. et al. Phase I trial of 1-(2′-deoxy-2′-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity. Invest New Drugs 1989, 7(2-3): 195-201. (Pubitemid 19202359)
90. Fanucchi, M.P., Leyland-Jones, B, Young, C.W. et al. Phase I trial of 1-(2′-deoxy-2′-fluoro-1-β-D-arabinofuranosyl)-5-methyluracil (FMAU). Cancer Treat Rep 1985, 69(1): 55-59
91. Conti, P.S., Bading, J.R., Mouton, P.P. et al. In vivo measurement of cell proliferation In canine brain tumor using C-11-labeled FMAU and PET. Nucl Med Biol 2008, 35(1): 131-141
92. Nishii, R., Volgin, A.Y., Mawlawi, O. et al. Evaluation of 2′-deoxy-2′[(18)F]fluoro-5-methyl-1-β-L-arabinofuranosyl) -uracil ([(18)F]-L-FMAU) as a PET imaging agent for cellular proliferation: Comparison with ([(18)F]-D-FMAU) and ([(18)F]-FLT. Eur J Nucl Med Mol Imaging 2008, 35(5): 900-98. ABSTRACT
93. McKenzie, R., Fried, M.W., Sallie, R. et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995, 333(17): 1099-1105.
94. Lewis, W, Levine, E.S., Griniuviene, B. et al. Fialuridine and its metabolites inhibit DNA polymerase γ at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatocytes. Proc Natl Acad Sci USA 1996, 93(8): 3592-3597 (Pubitemid 26125665)
95. Hu, R., Li, L., Degrève, B. et al. Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2′-deoxy-2′-fluoro-1-β-L-arabinofuranosyl)-5-methyluracil (clevudine) and 2′.3′-didehydro-2′,3′-dideoxythymidine in cells. Antmicrob Agents Chemother 2005, 49(5): 2044-2049 (Pubitemid 40631623)
96. Krishnan, P., Gullen, E.A., Lam, W. et al. Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside analogs, a new class of anticancer and antiviral agents. J Biol Chem 2003, 278(38): 36726-36732 (Pubitemid 37140005)
97. Gondeau, C., Chaloin, L., Lallemand, P. et al. Molecular basis for the lack of enantioselectivity of human 3-phosphoglycerate kinase. Nucl Acids Res 2008, 3620-3629 (Pubitemid 351917526)
98. Niu, C., Murakami, E., Furman, P.A. Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes. Antiviral Ther 2008, 13(2): 263-269
99. Niu, C., Murakami, E., Otto, M.J., Furman, P.A. Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes. Presented at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain, April 11-15, 2007. Available at http://www.pharmasset.com/pipeline/clevudine-publications.asp, accessed 18 June 2008.
100. Liu, S.-H., Grove, K.L., Cheng, Y.-C. Unique metabolism of a novel antiviral L-nucleoside analog, -2′-fluoro-5-methyl-β-L- arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob Agents Chemother 1998, 42(4): 833-839
101. Chu, C.K., Ma, T., Shanmuganathan, K. et al. Use of 2′-fluoro-5- methyl-β-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother 1995, 39(4): 979-981
102. Chu, C.K., Boudinot, F.D., Peek, S.F. et al. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antiviral Ther 1998, 3(suppl 3): 113-121
103. Kukhanova, M., Lin, Z.Y., Yas'co, M., Cheng, Y.C. Unique inhibitory effect of 1-(2′-deoxy-2′-fluoro-1-β-D-arabinofuranosyl)-5- methyluracil 5′-triphosphate on Epstein-Barr virus and human DNA polymerases. Biochem Pharmacol 1998, 55(8): 1181-1187
104. Abdelhamed, A. M., Kelley, C.M., Miller, T.G. et al. Comparison of anti-hepatitis-B virus activities of lamivudine and clevudine by a quantitative assay. Antimicrob Agents Chemother 2003, 47(1): 324-336 (Pubitemid 36070382)
105. Abdelhamed, A. M., Kelley, C.M., Miller, T.G. et al. Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment. J Virol 2002, 76(16): 8148-8160
106. Pai, S.B., Liu, S.-H., Zhu, Y.-L. et al. Inhibition of hepatitis B virus by a novel L-nudleoside, 2′-fluoro-5-methyl-β-L-arabinofuronosyl uracil. Antimicrob Agents Chemother 1996, 40(2): 380-386 (Pubitemid 26049351)
107. Chong, Y., Chu, C.K. Understanding the unique mechanism of L-FMAU (clevudine) against hepatitis B virus: Molecular dynamics studies. Bioorg Med Chem Lett 2002, 12(23): 3459-3462 (Pubitemid 35292469)
108. Sharon, A., Chu, C.K. Understanding the molecular basis of HBV drug resistance by molecular modeling. Antiviral Res 2008, 80(3): 339-353
109. Murakami, E., Wan, F., Furman, P.A. Novel mechanism of action of clevudine triphosphate: evidence for non-competitive inhibition of hepatitis B virus DNA polymerase. Presented at Frontiers in Drug Development in Viral Hepatitis (HEP-DART), Lahaina, Hawaii, December 9-13, 2007. Available at http://www.pharmasset.com/pipeline/clevudine-publications.asp, accessed 18 June 2008.
110. Zoulim, F. Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: Lesson from experimental models. J Antimicrob Chemother 2005, 55: 608-611 (Pubitemid 40691836)
111. Seignères, B., Pichoud, C., Martin, P. et al. Inhibitory activity ofdioxolone purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 2002, 36(3): 710-722 (Pubitemid 34977183)
112. Aguesse-Germon, S., Liu, S.-H., Chevallier, M. et al. Inhibitory effect of 2′-fluoro-5-methyl-β-L-arabinosyluracil on duck hepatitis B virus replication. Antimicrob Agents Chemother 1998, 42(2): 369-376 (Pubitemid 28114447)
113. Seignères, B., Martin, P., Werte, B. et al. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model. Antimicrob Agents Chemother 2003, 47(6): 1842-1852 (Pubitemid 36637804)
114. Peek, S.F., Cote, P.J., Jacob, J.R. et al. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-β,L-arabinofuranosyl)uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 2001, 33(1): 254-266
115. Summers, J., Mason, W.S. Residual Integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci USA 2004, 101(2): 638-640 (Pubitemid 38084689)
116. Jacquard, A.C., Nassal, M., Pichoud, C. et al. Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 2004, 48(7): 2683-2692 (Pubitemid 38823442)
117. Korba, B.E., Cote, P.J., Menne, S. et al. Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. Antiviral Ther 2004, 9(6): 937-952 (Pubitemid 40040268)
118. Menne, S., Roneker, C.A., Korba, B.E. et al. Immunization with surtace antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-β-L- arabinofuranosy)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis infection. J Virol 2002, 76(11): 5305-5314 (Pubitemid 34517881)
119. Menne, S., Tennant, B.C., Gerin, J.L., Cote, P.J. Chemoimmunotherapy of chronic hepatitis B virus infection in the woodchuck model overcomes immunologic tolerance and restores T-cell responses to pre-S and S regions of the viral envelope protein. J Virol 2007, 81(19): 10614-10624 (Pubitemid 47463335)
120. Lim, S.G., Krastev, Z., Ng, T.M. et al. Randomized, double-blind study of emtricitabine (FTC) plus clevudine vs. FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother 2006, 50(5):1642-1648
121. Lee, K.S., Byun, K.S., Chung, Y.H. et al. Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy. Intervirology 2007, 50(4): 296-302.
122. Ghany, M.G. Can hepatitis B be cured? In Hepatitis Annual Update 2008; eds. Craig, M.A., King, E, Schultz, J. Available at http://clinicaloptions.com/ Hepatitis/Annual%20Updates/2008%20Annual%20Update.aspx. Accessed 9 December 2008.
123. Lee, J., Yoo, B.C., Lee, H.S. et al. Rapid quantitative determination of L-FMAU-TP from human peripheral-blood mononuclear cells of hepatitis B virus-infected patients treated with L-FMAU by ion-pairing, reverse-phase, liquid chromatography/electrospray tandem mass spectroscopy. Ther Drug Monit 2006, 28(1): 131-137 (Pubitemid 44391707)
124. Byun, K.S., Yoo, B.C., Lee, K.S. et al. Hepatitis B surface antigen titer was decreased after clevudine therapy. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, Massachusetts, October 27-31, 2007. Available at http://aasld. scientificabstracts.org. Accessed 9 December 2008.
125. Marcellin, P., Mommega-Marin, H., Sacks, S.L. et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004, 40(1): 140-148 (Pubitemid 38868933)
126. Lee, H.-S., Chung, Y.-H., Lee, K. et al. A 12-week clevudine therapy showed potent and durable antiviral activity In HBeAg-positive chronic hepatitis B. Hepatology 2006, 43: 982-988 (Pubitemid 43724623)
127. Lim, S.G., Leung, N., Hann, H.L. et al. Clinical trial: A phase II, randomized study evaluating the safety, pharmacokinetics and antiviral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Aliment Pharmacol Ther 2008, 27(12): 1282-1292 (Pubitemid 351697275)
128. Chung, Y.-H., Lee, K.S., Kim, J.H. et al. A 48-week clevudine therapy demonstrated significant viral suppression and biochemical improvement in naïve patients with chronic hepatitis B [Study 303]. Presented at the 41st Annual Meeting of the European Association for the Study of the Liver (EASL), Vienna, Austria, April 26-30, 2006. Available at http://www.pharmasset.com/ pipeline/clevudine-publications.asp Accessed 9 December 2008.
129. Lee, H., Park, M., Kim, D. et al. Clevudine demonstrates potent antiviral activity in lamivudine-experienced patients. Abstract 902. Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, California, October 31-November 4, 2008. Available at http://aasld.scientificabstracts.org. Accessed 9 December 2008.
130. Sul, H., Kim, H, Lee, H. et al. The comparison of 24 weeks treatment efficacy between entecavir and clevudine in treatment-naive patiients with chronic hepatitis B. Abstract 912. Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, California, October 31-November 4, 2008. Available at http://aasld. scientificabstracts.org. Accessed 9 December 2008.
131. Chung, Y., Kim, J.A., Kim, S. et al. Add-on clevludine therapy in poteints with adefovir dipivoxil resistant chronic hepatitis B in comparison with add-on lamivudine therapy. Abstract 961. Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, California, October 31-November 4, 2008Available at http://aasld.scientificabstracts.org. Accessed 9 December 2008.
132. Yim, H., Kim, J., Jung, Y. et al. Early virologic and biochemical response to clevudine in cirrhotic patients with chronic HBV infection. Abstract 959. Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, California, October 31-November 4, 2008. Available at http://aasld.scientificabstracts.org. Accessed 9 December 2008.
133. Kang, M., Song, H., Jung, J. et al. One-year follow-up of biochemical and virologic al response to clevudine therapy in patients with chronic hepatitis B-associated cirrhosis. Abstract 968. Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, California, October 31-November 4, 2008. Available at http://aasld. scientificabstracts.org. Accessed 9 December 2008.
134. Chung, K.W., Chang, H.L., Lee, J.S. et al. Early biochemical and virological response of clevudine therapy in patients with HBV associated liver cirrhosis. Presented at Frontiers in Drug Development in Viral Hepatitis (HEP-DART), Lahaina, Hawaii, December 9-13, 2007. Available at http://www.pharmasset.com/pipeline/clevudine-publications.asp. Accessed 9 December 2008.
135. Lee, C.H., Chung, K.W., Lee, J.S. et al. Clevudine monotherapy showed rapid viral and biochemical response in chronic hepatitis B patients with cirrhosis. Presented at Frontiers in Drug Development in Viral Hepatitis (HEP-DART), Lahaina, Hawaii, December 9-13, 2007. Available at http://www.pharmasset.com/pipeline/clevudine-publications.asp. Accessed 9 December 2008.
136. Férer, G., Kaptein, S., Neyts, J. De Clercq, E. Antiviral treatment of chronic hepatitis B infections: The past, the present and the future. Rev Med Virol 2008, 18(1): 19-34.
137. Jacobson, I.M. Therapy of chronic hepatitis B: What to choose, when to change, and when to stop. In Hepatitis Annual Update 2008; eds. Craig, M.A., King, E, Schultz, J. Available at http://clinicaloptions.com/Hepatitis/ Annual%20Updates/2008%20Annual%20Update.aspx. 9 December 2008.
138. Wang, G.-F., Shi, L.-P., Zuo, J.-P. Anti-hepatitis B virus drugs in clinical and preclinical development. Virologica Sinica 2008, 23(2): 137-145.
139. Wu, G.-Y. Novel approaches towards conquering hepatitis B virus infection. World J Gastroenterol 2007, 13(6): 830-836 (Pubitemid 46470291)
140. Shamliyan, T.A., MacDonald, R., Shaukat, A. et al. Antiviral therapy for adults with chronic hepatitis B: A systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med 2009, 150(2): 111-24.
141. Elgouhari, H.M., Abu-Rajab Tamimi, T.I., Carey, W. Hepatitis B: A strategy for evaluation and management. Cleve Clin J Med 2009, 76(1): 19-35.
142. Coffin, C.S., Lee, S.S. Treatment of HBeAg-positive patients with nucleos/tide analogues. Liver Int 2009, 29(Suppl. 1): 116-124
143. Deval J. Antimicrobial strategies: Inhibition of viral polymerases by 3′-hydroxyl nucleosides. Drugs 2009, 69(2): 151-66.
144. Sharon, A., Chu, C.K. Understanding the molecular basis of HBV drug resistance by molecular modeling. Antiviral Res 2008, 80(3): 339-353
145. Kim, Y.S., Kim, G.H., Hwang, Y.J., Kwon, O.S., Choi, D.J., Kim, J.H. Early development of clevudine resistance during clevudine therapy in a patient with chronic hepatitis B who received prior lamivudine therapy. Liver Int J 2009, Jan 22, Epub ahead of print.
146. Seok, J.I., Lee, D.K., Lee, C.H., et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009, 49(6): 2080-2086
147. Pharmasset voluntarily terminates phase III QUASH clinical trials of clevudine in hepatitis B. DailyDrugNews.com (Daily Essentials) April 21, 2009.